ArticleNPJ genomic medicine2018
Clinical testing of
Open access · goldAbstract read
In one paragraph
Article in NPJ genomic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 60 citations in OpenAlex.
- Awareness of hereditary breast cancer and readiness for genetic testing among newly diagnosed patients with breast cancer in Nigeria: a multicentre study.Hereditary cancer in clinical practice · 2026Article
- Domain-Specific Computational, Functional and Structural Methods Enable Interpretation ofCurrent oncology (Toronto, Ont.) · 2026Article
- Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026Review
- Genetics services in Latin America: a descriptive study of availability and utilization of genetics in healthcare.Journal of community genetics · 2025Article
- Knowledge and perceptions of genetic testing for patients with breast cancer in Nigeria: a survey of healthcare providers.Hereditary cancer in clinical practice · 2025Article
- DNA damage response in breast cancer and its significant role in guiding novel precise therapies.Biomarker research · 2024Review
- Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.JAMA network open · 2024Article
- Assessment ofJCO clinical cancer informatics · 2024Article
- Challenges and Opportunities in Breast Cancer Care in Low-Resourced Countries, Jordan as An Example.Cancers · 2024Review
- Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants.Scientific reports · 2023Article
- Canine as a Comparative and Translational Model for Human Mammary Tumor.Journal of breast cancer · 2023Review
- Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake.Therapeutic advances in medical oncology · 2023Review
- Targeting theFrontiers in cell and developmental biology · 2023Review
- Global Oncology Medical Diplomacy Working Group Inaugural Meeting: Defining Worldwide Barriers to Germline Genomics in Cancer Prevention and Management.Annals of global health · 2023Article
- Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: A nationwide survey and calibration project in China.Prostate international · 2022Article
- Cell-type-specific epigenomic variations associated withNAR genomics and bioinformatics · 2022Article
- From the patient to the population: Use of genomics for population screening.Frontiers in genetics · 2022Article
- BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.Frontiers in cell and developmental biology · 2022Review
- Review
- A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 14 institutions in 7 countries.
Amanda Ewart Toland1Departments of Cancer Biology and Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210 USA.ORCID 0000-0002-0271-1792
Andrea Forman2Fox Chase Cancer Center, Philadelphia, PA 19111 USA.
Fergus J Couch3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905 USA.
Julie O Culver4USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 USA.
Diana M Eccles5Faculty of Medicine, University of Southampton, Southampton, S016 5YA UK.
William D Foulkes6Departments of Human Genetics, Medicine and Oncology, McGill University, Montreal, QC Canada H4A 3J1.ORCID 0000-0001-7427-4651
Frans B L Hogervorst7Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, 1006 BE Netherlands.
Claude Houdayer8Oncogenetics and INSERM U830, Institut Curie, Paris and Paris Descartes University, Paris, 75248 France.
Ephrat Levy-Lahad9Faculty of Medicine, Shaare Zedek Medical Center, Hebrew University of Jerusalem and Medical Genetics Institute, Jerusalem, 9103102 Israel.
Alvaro N Monteiro10Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612 USA.ORCID 0000-0002-8448-4801
Susan L Neuhausen11Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA 91010 USA.
Sharon E Plon12Baylor College of Medicine, Houston, TX 77030 USA.
Shyam K Sharan13Mouse Cancer Genetics Program, Center for Cancer Biology, National Cancer Institute, National Institutes of Health, Frederick, MD 21702-1201 USA.
Amanda B Spurdle14Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD QLD 4006 Australia.
Csilla Szabo15National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892 USA.
Lawrence C Brody15National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892 USA.
BIC Steering Committee
National Institutes of Health · USBaylor College of Medicine · USCancer Genetics (United States) · USCity of Hope · USDélégation Paris 5 · FRFox Chase Cancer Center · USHebrew University of Jerusalem · ILMayo Clinic · USMcGill University · CAMoffitt Cancer Center · USQIMR Berghofer Medical Research Institute · AUThe Netherlands Cancer Institute · NLUniversity of Southampton · GBUniversity of Southern California · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MFunctional Analysis of Variants Identified in Human Breast Cancer SusceptibilityZIABC011181 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2009 to 2025
$11.6MThe role of the BRCA1 and BRCA2 gene in the pathogenesis of breast cancerZIAHG000120 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BRODY, LAWRENCE C · 2009 to 2019
$980kNCI NIH HHS P30 CA016058
Abstract
Clinical testing of
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.